Dr. John Cush RheumNow
1 year 9 months ago
Steroids do NOT hamper muscle Bx dx of ANCA vasculitis. Tokyo study of 126 pts w/ suspected vasculitis had Quad muscle Bx; 71 (+) w/ Dx of AAV. Bx yield in 56 and 15 pts w/ off or on steroids, respectively, was similar (59% vs 53%). https://t.co/Xpt01Wksd3 https://t.co/NSBclcEgwq
Dr. John Cush RheumNow
1 year 9 months ago
Metanalysis of 41 studies, & 5343 AAV pts showed 55% (2890) had infection; 36% w/ severe infxn. This included PJP, aspergillosis, candidiasis, HZ, CMV, etc. Pulmonary most common. Risk factors included older, ESRD, DM, smoking, Renal or lung involvement https://t.co/4TtnP5wGc4 https://t.co/RatBXPUk7a
Dr. John Cush RheumNow
1 year 9 months ago
Rheumatoid Arthritis Boosts Risk for Some Types of Heart Failure
Rates of heart failure with preserved ejection fraction (HFpEF) were doubled in patients with rheumatoid arthritis (RA) relative to other people of the same age and sex, researchers found.… https://t.co/t7GRp7c63x https://t.co/Ov6UwGlPko
Abstract 1731 is a small RCT of baricitinib in inflammatory myositis comparing early start baricitinib to later start.
Dr. John Cush RheumNow
1 year 9 months ago
Japanese registry study of CV & CA outcomes in #RA. CV (MACE) events = IR 0.49/100 PY.
Cancer= IR 0.78/100PY. MACE risk factors: Male, age≥65, HTN, Renal or cerebrovascular Dz; CA risk w/ Male, age, NSAID, COPD, SIE, CA Hx. https://t.co/uBFbho25La https://t.co/3ClEwCvdDY
A Spanish Collaborative Group study of Tocilizumab (TCZ) in Giant Cell Arteritis (GCA) demonstrated high efficacy regardless of the different vascular phenotypes treated.
Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for these products -- even though biosimilars barely dented Humira prescription rates.
Dr. John Cush RheumNow
1 year 9 months ago
1st MTX use in 242 Italian pts w/ chronic inflam arthritis (54% RA, 33% PsA, 16% UA). Overall, survival of MTX at 24 months was 60%, (40% @48 mos, 20% @96 mos). MTX survival in RA & PsA equal, but superior to UA (undiff. arthritis) https://t.co/g4pZpVmTnM https://t.co/gcKWriqfhG
Dr. John Cush RheumNow
1 year 9 months ago
Serum IL-40 increased in RA (vs OA, SLE, Controls) and correlates with some clinical characteristics. IL-40 did not correlated w/ Dz activity, but was pos. assoc. w/ RA autoAbs, coagulation-related indicators, and decreased with TNFIi Rx. https://t.co/leBPKbNpf5 https://t.co/fHU8lcS4eW
Dr. John Cush RheumNow
1 year 9 months ago
International Map of Axial SpA study surveyed 5557 axSpA pts (3231 Europe, 770 USA); mean 44 yrs old; 55% females. mean BASDAI was 5.4 (75% had active disease -BASDAI ≥4). Active Dz highest in S. Africa 87%, vs 68% in Asia. Active Dz assoc w/ active functional limitation,… https://t.co/j8CjuLHHjD https://t.co/tV9S3b7YCM
Dr. John Cush RheumNow
1 year 9 months ago
Avacopan, a C5aR antagonist, for Rx of ANCA-Assoc GPA & MPA. Main warning for liver AE. In RCTs, abnl LFTs seen in 11.6-13.3% and 4.2% D/C drug for liver probs. Recent Japanese report of 22 AAV pts with AVACO Liver injury seen in 9 pts - Severe, incr total bilirubin in 4, 1 pt… https://t.co/LyuIQhwOoQ https://t.co/TAmQ9vph4V
Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and safety of treatments as well as outcomes and prognosis.
Dr. John Cush RheumNow
1 year 9 months ago
Although there is a bidirectional relationship betw pain and sleep, Sleep impairment more strongly predicts pain than pain does sleep. Addressing sleep disturbances is crucial, as it is linked to higher levels of disability, depression, pain-related catastrophizing.… https://t.co/pcFeCWSBCg https://t.co/0QlnbpKEbp
